<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00282685</url>
  </required_header>
  <id_info>
    <org_study_id>2005-000969-19</org_study_id>
    <secondary_id>RENERVATE</secondary_id>
    <nct_id>NCT00282685</nct_id>
  </id_info>
  <brief_title>Safety and Feasibility Study of Autologous Progenitor Cell Transplantation in Diabetic Neuropathy</brief_title>
  <official_title>(Restoration of Nerve Functions by Intra-arterial Transplantation of Bone Marrow Progenitor Cells in Patients With Diabetic Poly Neuropathy (PNP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of patients with diabetic neuropathy by intraarterial progenitor cell&#xD;
      transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Goal is:&#xD;
&#xD;
      Stimulation of angiogenesis and induction of vasa nervorum in order to improve nerve function&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of neurological score: modified NIS(LL)+7</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modified Toronto Clinical Scoring System</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate variability</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Diabetic Neuropathies</condition>
  <arm_group>
    <arm_group_label>Intra-arterial stemcell therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients were treated with intra-arterial stemcells delivered via catheter examination</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intraarterial bone marrow progenitor cell transplantation</intervention_name>
    <description>catheter delivery of stem cells</description>
    <arm_group_label>Intra-arterial stemcell therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with distal symmetrical diabetic neuropathy of the legs&#xD;
&#xD;
          -  Type 1 or Type 2 Diabetes&#xD;
&#xD;
          -  Stable Glucose control over last 3 months (Hba1c &lt;7.5)&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with peripheral arterial disease (ABI &lt;0.9)&#xD;
&#xD;
          -  Neuropathy of other origin&#xD;
&#xD;
          -  Myopathy&#xD;
&#xD;
          -  Asymmetrical neuropathy&#xD;
&#xD;
          -  Active infection oder fever&#xD;
&#xD;
          -  Chronic inflammatory disease (z.B M. Crohn, Rheumatoid Arthritis)&#xD;
&#xD;
          -  HIV or hepatitis&#xD;
&#xD;
          -  Neoplastic disease without complete remission within last 5 y&#xD;
&#xD;
          -  Stroke or myocardial infarction within last 3 months&#xD;
&#xD;
          -  Renal failure (creatinine &gt; 2 mg/dl)&#xD;
&#xD;
          -  Liver disease (GOT &gt; 2 upper limit or spontaneous INR &gt; 1,5).&#xD;
&#xD;
          -  Anemia (hemoglobine &lt; 8.5 mg/dl)&#xD;
&#xD;
          -  Platelets &lt;100.000/Âµl&#xD;
&#xD;
          -  HbA1c &gt;7,5 %&#xD;
&#xD;
          -  Allergies to Aspirin, Clopidogrel, Heparin&#xD;
&#xD;
          -  Bleeding disorder&#xD;
&#xD;
          -  Surgery or trauma within the last 2 months&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Mental retardation&#xD;
&#xD;
          -  Participation in another study within 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas M Zeiher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Div. of Cardiology, University of Frankfurt, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dirk H Walter, MD</last_name>
    <role>Study Director</role>
    <affiliation>Div. of Cardiology, University of Frankfurt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Div. of Cardiology and Vascular Medicine</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 25, 2006</study_first_submitted>
  <study_first_submitted_qc>January 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2006</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johann Wolfgang Goethe University Hospital</investigator_affiliation>
    <investigator_full_name>A. M. Zeiher</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>Patients with symmetric peripheral diabetic neuropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

